Infinity Bio
infinitybio.com
Actively hiring
Laboratory & Pharmaceutical Robotics
Bioinformatics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$22M
5 rounds on record
Latest round
$8M
Series A · Jun 2025 · 15 mo ago
Team
51-200
employees, estimated range
Backers
1
Illumina Ventures
The money's age
Due for its next round
15 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 17
New executive Infinity Bio Appoints Brian McKelligon as Chief Executive Officer · businesswire.com
Aug 13, 2025
Partnership Infinity Bio, Inc. Partners With the Austrian Institute of Technology to Provide Access to Antibody Reactome Profiling in Europe · businesswire.com
Jul 15, 2025
Launched Infinity Bio Launches EnviroSIGHT, the World's First Comprehensive Environmental Antibody Analysis Service · businesswire.com
Jun 13, 2025
Raised a round Venture round $5M · SEC Form D
Mar 4, 2025
Launched Infinity Bio Launches Comprehensive Mouse Antibody Reactome Profiling Service · businesswire.com
Feb 18, 2025
Took on debt financing $2M · SEC Form D
Oct 28, 2024
Recognition Infinity Bio Wins Gold at the 2024 MarCom Awards for Website Excellence · enter.amcpros.com
Sep 17, 2024
Launched Infinity Bio Unveils the World's Most Comprehensive Autoantibody Analysis Service: HuSIGHT-Total · businesswire.com
Jan 31, 2024
Launched Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology · businesswire.com
Jun 16, 2023
Raised a round Venture round $4.5M · SEC Form D
Jun 16, 2023
Raised a round Venture round $4.5M · SEC Form D
2023
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jun 2025 | $8M | Illumina Ventures lead, PTX Capital, Blackbird BioVentures, Propel Baltimore Fund | Nasdaq |
| Venture round | Jun 2025 | $5M | — | SEC Form D |
| Debt Financing | Feb 2025 | $2M | — | SEC Form D |
| Venture round | Jun 2023 | $4.5M | — | SEC Form D |
| Venture round | Jun 2023 | $4.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Infinity Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Benjamin LarmanExecutive Officer, DirectorSEC Form D
Caroline PopperDirectorSEC Form D
Joy NassifExecutive Officer, DirectorSEC Form D
H. LarmanExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
immunitoAI is an AI-driven biotechnology company accelerating antibody discovery and the development of antibody-based therapies through…
Explore Therapeutic Protein Libraries. For decades, therapeutic antibody discovery and optimization has been a shot in the Dark With the…
TareBio develops vaccines for cancer and infectious diseases by decoding immune responses to engineer targeted antigens.
Automate import and export compliance with AI-first screening, classification, export control, and market access intelligence—built to…
We work with you on making microbial growth predictable, scalable, and cost-effective through robotic lab automation and AI-driven insights.
A simple interface between scientists and lab automation.
News
Infinity Bio Appoints Brian McKelligon as Chief Executive Officer
Infinity Bio, a biotechnology company pioneering the MIPSA technology, today announced the appointment of Brian McKelligon as Chief Executive Officer. McKelligon, an accomplished leader with extensive experience building and scaling innovative life scienc
Read more
Report
Report
Infinity Bio, Inc. Partners With the Austrian Institute of Technology to Provide Access to Antibody Reactome Profiling in Europe
Infinity Bio service offerings leverage proprietary MIPSA technology to provide unprecedented insights into antibody reactivity for translational research and therapeutic development. The post Infinity Bio, Inc. Partners With the Austrian Institute of Tec
Read more
Report
Infinity Bio, Inc. Partners With the Austrian Institute of Technology to Provide Access to Antibody Reactome Profiling in Europe
Infinity Bio service offerings leverage proprietary MIPSA technology to provide unprecedented insights into antibody reactivity for translational research and therapeutic development. Infinity Bio
Read more
Report
Pro access
Upgrade to see all 19 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Benjamin Larman
Executive Officer, Director
Caroline Popper
Director
Joy Nassif
Executive Officer, Director
H. Larman
Executive Officer, Director
Matthew Hellauer
Director
Herman Scholtz
Director
Bill Campbell
Director
Malek Fahem
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Baltimore
United States
HQ
50-200 est. staff